On October 25, 2025, the Guangzhou Huirui factory, under Yangtze River Pharmaceutical Group (the Group), successfully completed the production of two batches of Parecoxib Sodium for Injection for the UK. The products are now ready to be shipped to the UK market. This smooth delivery is not only a strong testament to the efficient collaboration of the Group's international supply chain, but also a landmark breakthrough in the Group's strategic layout for the internationalization of high-end pharmaceutical formulations. It is the Group's first proprietary pharmaceutical product to successfully enter the highly regulated European market, marking the Group's international journey entering a new phase of high-quality development.
This milestone is a result of the teamwork within the production system. The team adhered strictly to EU GMP standards to ensure the products meet world-class quality. Moving forward, the group's production system will uphold the spirit of craftsmanship, promote more high-quality pharmaceuticals to enter the global market, and contribute to the health of consumers worldwide!
